aluates Reports

$ 0.0

Automative

Global Hematologic Malignancies Treatment Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-30A8912

Global Hematologic Malignancies Treatment Market Insights and Forecast to 2028

BUY CHAPTERS

Global Hematologic Malignancies Treatment Market Research Report 2025

Code: QYRE-Auto-30A8912

Report

March 2025

Pages:81

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bristol–Myers Squibb

Johnson & Johnson

AbbVie

Novartis

Roche

Amgen Inc

Takeda

Pfizer Inc

Astrazeneca plc

Gilead Sciences

BeiGene Ltd

INNOCARE

Suzhou Sinovent

Ono Pharmaceutical

TEVA

Hematologic Malignancies Treatment Market Size

The global market for Hematologic Malignancies Treatment was valued at US$ 71220 million in the year 2024 and is projected to reach a revised size of US$ 297860 million by 2031, growing at a CAGR of 23.0% during the forecast period.

Hematologic Malignancies Treatment Market

Hematological malignancy, also known as hematological disease, is a type of cancer impacting bone marrow, blood, and lymph nodes. Different sorts of mature blood cells include white blood cells for immune protection, platelets for wound clotting, and red blood cells to carry oxygen. In the bone marrow, it originates from progenitor cells and hematopoietic stem. Hematologic malignancies initiate in these cells and are subcategorized as per the type of blood cell that is affected such as myeloid or myelogenous or and lymphocytic lymphoblastic. A malignancy in the lymphoid lineage involves B lymphocytes and T lymphocytes. Malignancy in the myeloid lineage involves precursor cells to white blood cells platelets and red blood cells.

The hematologic malignancies treatment market is driven by several key factors, primarily the increasing incidence of blood cancers such as leukemia, lymphoma, and myeloma. With an aging global population, the prevalence of hematologic malignancies is on the rise, which drives the demand for advanced and effective therapies. The growing understanding of the molecular biology behind these cancers has paved the way for more targeted treatments, including immunotherapies, CAR-T cell therapies, and small molecule inhibitors. Furthermore, ongoing research and development in the field of hematology have led to the introduction of new, more effective treatments, enhancing survival rates and improving patient outcomes, thereby fueling market growth.

However, the market faces significant challenges, including the high cost of novel therapies and limited access to these treatments in low-income regions. Cutting-edge treatments, such as gene therapies and immunotherapies, come with high price tags, which may restrict access for a large portion of the population. Additionally, the complexity of treatment regimens, which often require personalized care and long-term monitoring, can create barriers in healthcare systems with limited resources. Moreover, the side effects and long-term safety concerns associated with some of these advanced treatments pose another challenge, requiring further research and regulatory approval to ensure patient safety and efficacy.

Global key hematologic malignancies treatment manufacturers include Bristol-Myers Squibb, Johnson & Johnson, AbbVie etc. The top 3 company hold a share about 60%. North America is the largest market, with a share about 50%, followed by Europe and Asia-Pacific with the share both about 22%. In terms of product, chemotherapy is the largest segment, with a share over 30%. And in terms of application, the largest application is leukemia, followed by lymphoma and multiple myeloma.

This report aims to provide a comprehensive presentation of the global market for Hematologic Malignancies Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematologic Malignancies Treatment.

The Hematologic Malignancies Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hematologic Malignancies Treatment market comprehensively. Regional market sizes, concerning products by Type, by Disease, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hematologic Malignancies Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Disease, and by regions.

Market Segmentation

Scope of Hematologic Malignancies Treatment Market Report

Report Metric	Details
Report Name	Hematologic Malignancies Treatment Market
Accounted market size in year	US$ 71220 million
Forecasted market size in 2031	US$ 297860 million
CAGR	23.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Chemotherapy Targeted Therapy Immunotherapy
Segment by Disease	Leukemia Lymphoma Multiple Myeloma Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer, AstraZeneca, Gilead Sciences, BeiGene, INNOCARE, Suzhou Sinovent, Ono Pharmaceutical, Teva
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Disease, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hematologic Malignancies Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Disease, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Hematologic Malignancies Treatment Market growing?

Ans: The Hematologic Malignancies Treatment Market witnessing a CAGR of 23.0% during the forecast period 2025-2031.

What is the Hematologic Malignancies Treatment Market size in 2031?

Ans: The Hematologic Malignancies Treatment Market size in 2031 will be US$ 297860 million.

What is the Hematologic Malignancies Treatment Market share by type?

Ans: In terms of product, chemotherapy is the largest segment, with a share over 30%.

Who are the main players in the Hematologic Malignancies Treatment Market report?

Ans: The main players in the Hematologic Malignancies Treatment Market are Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer, AstraZeneca, Gilead Sciences, BeiGene, INNOCARE, Suzhou Sinovent, Ono Pharmaceutical, Teva

What are the Type segmentation covered in the Hematologic Malignancies Treatment Market report?

Ans: The Types covered in the Hematologic Malignancies Treatment Market report are Chemotherapy, Targeted Therapy, Immunotherapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hematologic Malignancies Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Chemotherapy

1.2.3 Targeted Therapy

1.2.4 Immunotherapy

1.3 Market by Disease

1.3.1 Global Hematologic Malignancies Treatment Market Growth by Disease: 2020 VS 2024 VS 2031

1.3.2 Leukemia

1.3.3 Lymphoma

1.3.4 Multiple Myeloma

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Hematologic Malignancies Treatment Market Perspective (2020-2031)

2.2 Global Hematologic Malignancies Treatment Growth Trends by Region

2.2.1 Global Hematologic Malignancies Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Hematologic Malignancies Treatment Historic Market Size by Region (2020-2025)

2.2.3 Hematologic Malignancies Treatment Forecasted Market Size by Region (2026-2031)

2.3 Hematologic Malignancies Treatment Market Dynamics

2.3.1 Hematologic Malignancies Treatment Industry Trends

2.3.2 Hematologic Malignancies Treatment Market Drivers

2.3.3 Hematologic Malignancies Treatment Market Challenges

2.3.4 Hematologic Malignancies Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hematologic Malignancies Treatment Players by Revenue

3.1.1 Global Top Hematologic Malignancies Treatment Players by Revenue (2020-2025)

3.1.2 Global Hematologic Malignancies Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Hematologic Malignancies Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Hematologic Malignancies Treatment Revenue

3.4 Global Hematologic Malignancies Treatment Market Concentration Ratio

3.4.1 Global Hematologic Malignancies Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Treatment Revenue in 2024

3.5 Global Key Players of Hematologic Malignancies Treatment Head office and Area Served

3.6 Global Key Players of Hematologic Malignancies Treatment, Product and Application

3.7 Global Key Players of Hematologic Malignancies Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Hematologic Malignancies Treatment Breakdown Data by Type

4.1 Global Hematologic Malignancies Treatment Historic Market Size by Type (2020-2025)

4.2 Global Hematologic Malignancies Treatment Forecasted Market Size by Type (2026-2031)

5 Hematologic Malignancies Treatment Breakdown Data by Disease

5.1 Global Hematologic Malignancies Treatment Historic Market Size by Disease (2020-2025)

5.2 Global Hematologic Malignancies Treatment Forecasted Market Size by Disease (2026-2031)

6 North America

6.1 North America Hematologic Malignancies Treatment Market Size (2020-2031)

6.2 North America Hematologic Malignancies Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Hematologic Malignancies Treatment Market Size by Country (2020-2025)

6.4 North America Hematologic Malignancies Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Hematologic Malignancies Treatment Market Size (2020-2031)

7.2 Europe Hematologic Malignancies Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Hematologic Malignancies Treatment Market Size by Country (2020-2025)

7.4 Europe Hematologic Malignancies Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Hematologic Malignancies Treatment Market Size (2020-2031)

8.2 Asia-Pacific Hematologic Malignancies Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Hematologic Malignancies Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Hematologic Malignancies Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Hematologic Malignancies Treatment Market Size (2020-2031)

9.2 Latin America Hematologic Malignancies Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Hematologic Malignancies Treatment Market Size by Country (2020-2025)

9.4 Latin America Hematologic Malignancies Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hematologic Malignancies Treatment Market Size (2020-2031)

10.2 Middle East & Africa Hematologic Malignancies Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Hematologic Malignancies Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Hematologic Malignancies Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bristol-Myers Squibb

11.1.1 Bristol-Myers Squibb Company Details

11.1.2 Bristol-Myers Squibb Business Overview

11.1.3 Bristol-Myers Squibb Hematologic Malignancies Treatment Introduction

11.1.4 Bristol-Myers Squibb Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.1.5 Bristol-Myers Squibb Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Details

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Hematologic Malignancies Treatment Introduction

11.2.4 Johnson & Johnson Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.2.5 Johnson & Johnson Recent Development

11.3 AbbVie

11.3.1 AbbVie Company Details

11.3.2 AbbVie Business Overview

11.3.3 AbbVie Hematologic Malignancies Treatment Introduction

11.3.4 AbbVie Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.3.5 AbbVie Recent Development

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Novartis Business Overview

11.4.3 Novartis Hematologic Malignancies Treatment Introduction

11.4.4 Novartis Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.4.5 Novartis Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Hematologic Malignancies Treatment Introduction

11.5.4 Roche Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.5.5 Roche Recent Development

11.6 Amgen

11.6.1 Amgen Company Details

11.6.2 Amgen Business Overview

11.6.3 Amgen Hematologic Malignancies Treatment Introduction

11.6.4 Amgen Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.6.5 Amgen Recent Development

11.7 Takeda

11.7.1 Takeda Company Details

11.7.2 Takeda Business Overview

11.7.3 Takeda Hematologic Malignancies Treatment Introduction

11.7.4 Takeda Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.7.5 Takeda Recent Development

11.8 Pfizer

11.8.1 Pfizer Company Details

11.8.2 Pfizer Business Overview

11.8.3 Pfizer Hematologic Malignancies Treatment Introduction

11.8.4 Pfizer Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.8.5 Pfizer Recent Development

11.9 AstraZeneca

11.9.1 AstraZeneca Company Details

11.9.2 AstraZeneca Business Overview

11.9.3 AstraZeneca Hematologic Malignancies Treatment Introduction

11.9.4 AstraZeneca Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.9.5 AstraZeneca Recent Development

11.10 Gilead Sciences

11.10.1 Gilead Sciences Company Details

11.10.2 Gilead Sciences Business Overview

11.10.3 Gilead Sciences Hematologic Malignancies Treatment Introduction

11.10.4 Gilead Sciences Revenue in Hematologic Malignancies Treatment Business (2020-2025)

11.10.5 Gilead Sciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Bristol–Myers Squibb

Johnson & Johnson

AbbVie

Novartis

Roche

Amgen Inc

Takeda

Pfizer Inc

Astrazeneca plc

Gilead Sciences

BeiGene Ltd

INNOCARE

Suzhou Sinovent

Ono Pharmaceutical

TEVA

List of Tables

Table 1. Global Hematologic Malignancies Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Chemotherapy

Table 3. Key Players of Targeted Therapy

Table 4. Key Players of Immunotherapy

Table 5. Global Hematologic Malignancies Treatment Market Size Growth by Disease (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Hematologic Malignancies Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Hematologic Malignancies Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Hematologic Malignancies Treatment Market Share by Region (2020-2025)

Table 9. Global Hematologic Malignancies Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Hematologic Malignancies Treatment Market Share by Region (2026-2031)

Table 11. Hematologic Malignancies Treatment Market Trends

Table 12. Hematologic Malignancies Treatment Market Drivers

Table 13. Hematologic Malignancies Treatment Market Challenges

Table 14. Hematologic Malignancies Treatment Market Restraints

Table 15. Global Hematologic Malignancies Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Hematologic Malignancies Treatment Market Share by Players (2020-2025)

Table 17. Global Top Hematologic Malignancies Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematologic Malignancies Treatment as of 2024)

Table 18. Ranking of Global Top Hematologic Malignancies Treatment Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Hematologic Malignancies Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Hematologic Malignancies Treatment, Headquarters and Area Served

Table 21. Global Key Players of Hematologic Malignancies Treatment, Product and Application

Table 22. Global Key Players of Hematologic Malignancies Treatment, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Hematologic Malignancies Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Hematologic Malignancies Treatment Revenue Market Share by Type (2020-2025)

Table 26. Global Hematologic Malignancies Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Hematologic Malignancies Treatment Revenue Market Share by Type (2026-2031)

Table 28. Global Hematologic Malignancies Treatment Market Size by Disease (2020-2025) & (US$ Million)

Table 29. Global Hematologic Malignancies Treatment Revenue Market Share by Disease (2020-2025)

Table 30. Global Hematologic Malignancies Treatment Forecasted Market Size by Disease (2026-2031) & (US$ Million)

Table 31. Global Hematologic Malignancies Treatment Revenue Market Share by Disease (2026-2031)

Table 32. North America Hematologic Malignancies Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Hematologic Malignancies Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Hematologic Malignancies Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Hematologic Malignancies Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Hematologic Malignancies Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Hematologic Malignancies Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Hematologic Malignancies Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Hematologic Malignancies Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Hematologic Malignancies Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Hematologic Malignancies Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Hematologic Malignancies Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Hematologic Malignancies Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Hematologic Malignancies Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Hematologic Malignancies Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Hematologic Malignancies Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 47. Bristol-Myers Squibb Company Details

Table 48. Bristol-Myers Squibb Business Overview

Table 49. Bristol-Myers Squibb Hematologic Malignancies Treatment Product

Table 50. Bristol-Myers Squibb Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 51. Bristol-Myers Squibb Recent Development

Table 52. Johnson & Johnson Company Details

Table 53. Johnson & Johnson Business Overview

Table 54. Johnson & Johnson Hematologic Malignancies Treatment Product

Table 55. Johnson & Johnson Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 56. Johnson & Johnson Recent Development

Table 57. AbbVie Company Details

Table 58. AbbVie Business Overview

Table 59. AbbVie Hematologic Malignancies Treatment Product

Table 60. AbbVie Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 61. AbbVie Recent Development

Table 62. Novartis Company Details

Table 63. Novartis Business Overview

Table 64. Novartis Hematologic Malignancies Treatment Product

Table 65. Novartis Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 66. Novartis Recent Development

Table 67. Roche Company Details

Table 68. Roche Business Overview

Table 69. Roche Hematologic Malignancies Treatment Product

Table 70. Roche Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 71. Roche Recent Development

Table 72. Amgen Company Details

Table 73. Amgen Business Overview

Table 74. Amgen Hematologic Malignancies Treatment Product

Table 75. Amgen Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 76. Amgen Recent Development

Table 77. Takeda Company Details

Table 78. Takeda Business Overview

Table 79. Takeda Hematologic Malignancies Treatment Product

Table 80. Takeda Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 81. Takeda Recent Development

Table 82. Pfizer Company Details

Table 83. Pfizer Business Overview

Table 84. Pfizer Hematologic Malignancies Treatment Product

Table 85. Pfizer Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 86. Pfizer Recent Development

Table 87. AstraZeneca Company Details

Table 88. AstraZeneca Business Overview

Table 89. AstraZeneca Hematologic Malignancies Treatment Product

Table 90. AstraZeneca Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 91. AstraZeneca Recent Development

Table 92. Gilead Sciences Company Details

Table 93. Gilead Sciences Business Overview

Table 94. Gilead Sciences Hematologic Malignancies Treatment Product

Table 95. Gilead Sciences Revenue in Hematologic Malignancies Treatment Business (2020-2025) & (US$ Million)

Table 96. Gilead Sciences Recent Development

Table 97. Research Programs/Design for This Report

Table 98. Key Data Information from Secondary Sources

Table 99. Key Data Information from Primary Sources

Table 100. Authors List of This Report

List of Figures

Figure 1. Hematologic Malignancies Treatment Picture

Figure 2. Global Hematologic Malignancies Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hematologic Malignancies Treatment Market Share by Type: 2024 VS 2031

Figure 4. Chemotherapy Features

Figure 5. Targeted Therapy Features

Figure 6. Immunotherapy Features

Figure 7. Global Hematologic Malignancies Treatment Market Size by Disease (2020-2031) & (US$ Million)

Figure 8. Global Hematologic Malignancies Treatment Market Share by Disease: 2024 VS 2031

Figure 9. Leukemia Case Studies

Figure 10. Lymphoma Case Studies

Figure 11. Multiple Myeloma Case Studies

Figure 12. Others Case Studies

Figure 13. Hematologic Malignancies Treatment Report Years Considered

Figure 14. Global Hematologic Malignancies Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Hematologic Malignancies Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Hematologic Malignancies Treatment Market Share by Region: 2024 VS 2031

Figure 17. Global Hematologic Malignancies Treatment Market Share by Players in 2024

Figure 18. Global Top Hematologic Malignancies Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematologic Malignancies Treatment as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Hematologic Malignancies Treatment Revenue in 2024

Figure 20. North America Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Hematologic Malignancies Treatment Market Share by Country (2020-2031)

Figure 22. United States Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Hematologic Malignancies Treatment Market Share by Country (2020-2031)

Figure 26. Germany Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Hematologic Malignancies Treatment Market Share by Region (2020-2031)

Figure 34. China Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Hematologic Malignancies Treatment Market Share by Country (2020-2031)

Figure 42. Mexico Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Hematologic Malignancies Treatment Market Share by Country (2020-2031)

Figure 46. Turkey Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Hematologic Malignancies Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 50. Johnson & Johnson Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 51. AbbVie Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 52. Novartis Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 53. Roche Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 54. Amgen Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 55. Takeda Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 56. Pfizer Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 57. AstraZeneca Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 58. Gilead Sciences Revenue Growth Rate in Hematologic Malignancies Treatment Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Blood Tumor Treatment Market Research Report 2024

Global Blood Tumor Drugs Market Research Report 2024

Global Hematological Cancers Market Research Report 2024

Global Targeted Drug for Blood Cancers Market Research Report 2024

Global Blood Cancer Treatments Market Research Report 2024

Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hematologic Malignancies Detection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hematology Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Blood Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hematology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drug for Leukemia Market Research Report 2024

Global Targeted Therapy Drugs for Leukemia Market Research Report 2024

Drugs for Hematology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hematology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Myeloproliferative Disorders Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Blood and Bone Marrow Cancer Treatment Market Insights Forecast to 2030

Global Blood Cancer Therapeutics Market Insights Forecast to 2030

Global Follicular Lymphoma Treatment Market Research Report 2025

Global Acute Lymphoid Leukemia Treatment Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions